FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171512247> ?p ?o ?g. }

• W2171512247 endingPage "2643" @default.
• W2171512247 startingPage "2638" @default.
• W2171512247 abstract "OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C &lt;7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone." @default.
• W2171512247 created "2016-06-24" @default.
• W2171512247 creator A5025169113 @default.
• W2171512247 creator A5031383176 @default.
• W2171512247 creator A5031542137 @default.
• W2171512247 creator A5040802687 @default.
• W2171512247 creator A5049225160 @default.
• W2171512247 date "2006-12-01" @default.
• W2171512247 modified "2023-09-25" @default.
• W2171512247 title "Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone" @default.
• W2171512247 cites W1994743271 @default.
• W2171512247 cites W2042587216 @default.
• W2171512247 cites W2054185381 @default.
• W2171512247 cites W2068183831 @default.
• W2171512247 cites W2069150029 @default.
• W2171512247 cites W2074511950 @default.
• W2171512247 cites W2083473802 @default.
• W2171512247 cites W2102643655 @default.
• W2171512247 cites W2104763836 @default.
• W2171512247 cites W2154615287 @default.
• W2171512247 cites W2161075296 @default.
• W2171512247 cites W4230518743 @default.
• W2171512247 doi "https://doi.org/10.2337/dc06-0706" @default.
• W2171512247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17130197" @default.
• W2171512247 hasPublicationYear "2006" @default.
• W2171512247 type Work @default.
• W2171512247 sameAs 2171512247 @default.
• W2171512247 citedByCount "721" @default.
• W2171512247 countsByYear W21715122472012 @default.
• W2171512247 countsByYear W21715122472013 @default.
• W2171512247 countsByYear W21715122472014 @default.
• W2171512247 countsByYear W21715122472015 @default.
• W2171512247 countsByYear W21715122472016 @default.
• W2171512247 countsByYear W21715122472017 @default.
• W2171512247 countsByYear W21715122472018 @default.
• W2171512247 countsByYear W21715122472019 @default.
• W2171512247 countsByYear W21715122472020 @default.
• W2171512247 countsByYear W21715122472021 @default.
• W2171512247 countsByYear W21715122472022 @default.
• W2171512247 countsByYear W21715122472023 @default.
• W2171512247 crossrefType "journal-article" @default.
• W2171512247 hasAuthorship W2171512247A5025169113 @default.
• W2171512247 hasAuthorship W2171512247A5031383176 @default.
• W2171512247 hasAuthorship W2171512247A5031542137 @default.
• W2171512247 hasAuthorship W2171512247A5040802687 @default.
• W2171512247 hasAuthorship W2171512247A5049225160 @default.
• W2171512247 hasBestOaLocation W21715122471 @default.
• W2171512247 hasConcept C126322002 @default.
• W2171512247 hasConcept C134018914 @default.
• W2171512247 hasConcept C142724271 @default.
• W2171512247 hasConcept C204787440 @default.
• W2171512247 hasConcept C27081682 @default.
• W2171512247 hasConcept C2776453732 @default.
• W2171512247 hasConcept C2776652674 @default.
• W2171512247 hasConcept C2777180221 @default.
• W2171512247 hasConcept C2778763485 @default.
• W2171512247 hasConcept C2779284873 @default.
• W2171512247 hasConcept C2779306644 @default.
• W2171512247 hasConcept C2780323712 @default.
• W2171512247 hasConcept C2780473172 @default.
• W2171512247 hasConcept C2908647359 @default.
• W2171512247 hasConcept C2910260750 @default.
• W2171512247 hasConcept C555293320 @default.
• W2171512247 hasConcept C71924100 @default.
• W2171512247 hasConcept C90924648 @default.
• W2171512247 hasConcept C98274493 @default.
• W2171512247 hasConcept C99454951 @default.
• W2171512247 hasConceptScore W2171512247C126322002 @default.
• W2171512247 hasConceptScore W2171512247C134018914 @default.
• W2171512247 hasConceptScore W2171512247C142724271 @default.
• W2171512247 hasConceptScore W2171512247C204787440 @default.
• W2171512247 hasConceptScore W2171512247C27081682 @default.
• W2171512247 hasConceptScore W2171512247C2776453732 @default.
• W2171512247 hasConceptScore W2171512247C2776652674 @default.
• W2171512247 hasConceptScore W2171512247C2777180221 @default.
• W2171512247 hasConceptScore W2171512247C2778763485 @default.
• W2171512247 hasConceptScore W2171512247C2779284873 @default.
• W2171512247 hasConceptScore W2171512247C2779306644 @default.
• W2171512247 hasConceptScore W2171512247C2780323712 @default.
• W2171512247 hasConceptScore W2171512247C2780473172 @default.
• W2171512247 hasConceptScore W2171512247C2908647359 @default.
• W2171512247 hasConceptScore W2171512247C2910260750 @default.
• W2171512247 hasConceptScore W2171512247C555293320 @default.
• W2171512247 hasConceptScore W2171512247C71924100 @default.
• W2171512247 hasConceptScore W2171512247C90924648 @default.
• W2171512247 hasConceptScore W2171512247C98274493 @default.
• W2171512247 hasConceptScore W2171512247C99454951 @default.
• W2171512247 hasIssue "12" @default.
• W2171512247 hasLocation W21715122471 @default.
• W2171512247 hasLocation W21715122472 @default.
• W2171512247 hasOpenAccess W2171512247 @default.
• W2171512247 hasPrimaryLocation W21715122471 @default.
• W2171512247 hasRelatedWork W1546635462 @default.
• W2171512247 hasRelatedWork W1985523042 @default.
• W2171512247 hasRelatedWork W1987248351 @default.
• W2171512247 hasRelatedWork W2097893376 @default.
• W2171512247 hasRelatedWork W2147774754 @default.
• W2171512247 hasRelatedWork W2301714968 @default.

• next